Man with glasses in front of microscope.

Cardiac Rhythm Management

Our focus

Groundbreaking technologies that monitor, support diagnosis, and treat irregular heart rhythms, heart failure and sudden cardiac arrest.

Kevin’s story

We are collaborating with healthcare professionals to help improve outcomes, enhance patients' lives, and reduce costs with the most advanced and least invasive cardiac rhythm management monitoring and therapeutic technologies available.

Delivering meaningful innovation

Improving patient management through personalized care.

Our MR-conditional Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems feature the HeartLogic™ Heart Failure Diagnostic to help physicians improve heart failure (HF) management. SmartCRT™ Technology incorporated in the devices helps physicians determine where, when and how to pace, while industry-leading device longevity is provided through EnduraLife™ Battery Technology.

Pioneering progressive ICD therapy.

The EMBLEM™ MRI S-ICD System is the only MR-conditional subcutaneous implantable defibrillator (S-ICD) that provides protection for patients at risk for sudden cardiac death. Because it provides protection without touching the heart or substernal space, the device eliminates many of the complications associated with transvenous leads placed in those locations. The EMBLEM S-ICD System is placed entirely outside the rib cage and just beneath the skin of a patient, and avoids complications associated with more invasive leads.

For the rhythms of life.

Boston Scientific Cardiac Diagnostics, a wholly owned subsidiary of Boston Scientific, provides mobile health solutions and remote monitoring services that connect physicians with patients threatened by cardiac arrhythmias. The BodyGuardian™ family of remote, wearable cardiac monitors is led by sophisticated ambulatory cardiac monitoring technology, and along with the PatientCare platform offers near real-time analysis of ambulatory echocardiogram data designed to support clinical diagnosis and outcomes. The BeatLogic technology applies artificial intelligence to support clinician decision making.

check icon

S-ICD: The only subcutaneous implantable defibrillator.

check icon

Nearly 2x the usable battery capacity of Medtronic ICDs.¹

check icon

HeartLogic: 70% sensitivity in detecting heart failure events several weeks in advance.²

Conditions we treat

  • Heart Rhythm Disorders
  • Sudden Cardiac Arrest
  • Heart Failure

≈6.7M

An estimated 6.7M American adults were diagnosed with heart failure between 2017 and 2020.3

356K+

More than 356K people experience out-of-hospital cardiac arrests annually in the U.S., and nearly 90% of those incidents are fatal.4

~280K

In 2016, approximately 280K emergency visits in the U.S. were for tachycardias and another 115K were for bradycardias.5

≈38M

An estimated 38M people globally have atrial fibrillation (Afib).5

~13%

Approximately 13% of the estimated 5.3 million cases of Afib in the U.S. are undiagnosed.6

Solutions offered

  • Pacemakers
  • Implantable cardioverter defibrillators (ICDs)
  • Subcutaneous implantable defibrillator (S-ICD)
  • Cardiac resynchronization therapy defibrillators (CRT-Ds)
  • Remote monitoring systems
  • Pacing and ICD leads
  • Insertable cardiac monitors (ICMs)
  • Wearable monitors and services (through Boston Scientific Cardiac Diagnostics)

Product spotlights

Image of RESONATE™ X4 CRT-D Powered by EnduraLife - Boston Scientific Resonate™

Resonate™

The ResonateTM family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems feature the HeartLogicTM Heart Failure Diagnostic. The Resonate devices, which are approved by the U.S. Food and Drug Administration for conditional use in a magnetic resonance imaging (MRI) environment, also incorporate SmartCRT™ Technology, which helps physicians determine where, when and how to pace, while industry-leading device longevity is provided through EnduraLife™ Battery Technology.

Learn more about the Resonate familiy of ICD and CRT-D Systems
Image of  EMBLEMTM MRI S-ICD System

EMBLEM™ MRI S-ICD System

The EMBLEM™ MRI S-ICD System is the only subcutaneous implantable defibrillator that provides protection for patients at risk for sudden cardiac death while remaining entirely outside the rib cage and just beneath the skin of a patient.

Learn more about the EMBLEM MRI S-ICD System
Image of LUX-Dx™ Insertable Cardiac Monitor

LUX-Dx II+™ Insertable Cardiac Monitor System

The LUX-Dx II+ Insertable Cardiac Monitor (ICM) System is a long-term diagnostic device inserted under the skin of patients to detect arrhythmias associated with conditions such as atrial fibrillation, cryptogenic stroke and syncope. Designed with a dual-stage algorithm that detects and then verifies potential arrhythmias before an alert is sent to clinicians, it has an intuitive implant procedure and allows for remote programming.

Learn more about the LUX-Dx II+ ICM System
Image of Preventice Solutions BodyGuardian® MINI

BodyGuardian™ MINI PLUS

Boston Scientific Cardiac Diagnostics, a wholly owned subsidiary of Boston Scientific, provides the BodyGuardian™ MINI PLUS which is a small, reusable, four-in-one cardiac monitoring device that includes mobile cardiac telemetry, cardiac event monitoring, and short- and long-term holter monitoring services. Unlike many monitors, the BodyGuardian MINI PLUS has multiple placement options and offers a wearable patch that can be moved and reapplied to optimize comfort and wearability. During the monitoring period it can be replaced without jeopardizing data collection or requiring patients to return to the clinic, and its waterproof design allows patients the freedom to go about their daily routine without interrupting cardiac monitoring.

Learn more about the Boston Scientific Cardiac Diagnostics BodyGuardian MINI PLUS

Reference

  1. Ellis C, Markus T, Dickerman D, Orton J, Hassan S, Good E, Okabe T, Greenspon A. Ampere Hour as a Predictor of CRT ICD Pulse Generator Longevity: A Multi-Center Study. Presented at HFSA 2014. https://www.onlinejcf.com/article/S1071-9164(14)00337-6/fulltext. Ampere Hour (Ah) as a Predictor of CRT ICD Pulse Generator Battery Longevity Study. The five major institutions performing the study include, at Vanderbilt University, Eastside Cardiovascular Medicine, University of Michigan, Thomas Jefferson University, Robert Wood Johnson University Hospital, Cooper Health System and North Ohio Research. Boston Scientific = 266 patients, Medtronic = 542 patients, St. Jude Medical = 149 patients. Five-year survival rate calculated using device replacements for battery depletion as indicated by ERI.
  2. Boehmer, JP, Hariharan R, Devecchi FG, et al. A multisensor algorithm predicts heart failure events in patients with implanted devices; Results from the MultiSENSE study. JACC Heart Fail. 2017 Mar:5(3)216-25.
  3.  https://doi.org/10.1161/CIR.0000000000001123 |Circulation. 2023;147:e93–e621
  4. According to the Healthcare Cost and Utilization Project (HCUP) data. Source: https://www.ahrq.gov/data/hcup/index.html
  5. Lippi G, Sanchis-Gomar F., et al. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021; Feb 16:217-221.
  6. Turakhia MP, Shafrin J, Bognar K, et al. Estimated prevalence of undiagnosed atrial fibrillation in the United States. PLoS One. 2018;13(4):e